{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:02:20Z","timestamp":1777489340248,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T00:00:00Z","timestamp":1414022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union's 6th framework","award":["037777"],"award-info":[{"award-number":["037777"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective.<\/jats:title><jats:p>The study objective was to evaluate whether there are clinical or genetic differences between patients with cancer-induced bone pain (CIBP) and patients with non-CIBP, and, in the CIBP group, in those with good versus poor opioid response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods.<\/jats:title><jats:p>A total of 2,294 adult patients with cancer who were receiving opioids for moderate or severe pain were included in the European Pharmacogenetic Opioid Study. Pain intensity and pain relief were measured using the Brief Pain Inventory. Linkage disequilibrium of 112 single nucleotide polymorphisms was evaluated in 25 candidate genes, and 43 haplotypes were assessed. Correlations among demographical factors, disease-related factors, genetic factors, CIBP, and pain relief were analyzed by logistic regression models corrected for multiple testing. Patients with bone metastases and bone\/soft tissue pain were defined as having prevalent bone pain (CIBP population). This population was compared with patients who had other types of cancer pain (non-CIBP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 577 patients (26.2%) had CIBP, and 1,624 patients (73.8%) had non-CIBP. Patients with CIBP had more breakthrough cancer pain episodes (64.2% vs. 56.4%, p = .001), had significantly higher pain interference in \u201cwalking ability in the past 24 hours\u201d (p &amp;lt; .0001), used more adjuvant drugs (84.1% vs. 78.3%, p = .003), and had a higher, albeit nonsignificant, median overall survival (3.8 vs. 2.9 months, p = .716) than patients with non-CIBP. None of the examined haplotypes exceeded p values corrected for multiple testing for the investigated outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group. However, no specific genetic pattern emerged for CIBP versus non-CIBP or for responsive versus nonresponsive patients with CIBP.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0174","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T06:33:04Z","timestamp":1414132384000},"page":"1276-1283","source":"Crossref","is-referenced-by-count":10,"title":["Clinical and Genetic Factors Related to Cancer-Induced Bone Pain and Bone Pain Relief"],"prefix":"10.1093","volume":"19","author":[{"given":"Emanuela","family":"Scarpi","sequence":"first","affiliation":[{"name":"Biostatistics and Clinical Trials Unit, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Calistri","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, St. Olavs University Hospital, Trondheim, Norway;"},{"name":"Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway;"},{"name":"European Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Trondheim, Norway"},{"name":"Department of Circulation and Medical Imaging, Children's and Women's Health and European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Skorpen","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Trondheim, Norway"},{"name":"Department of Laboratory Medicine, Children's and Women's Health and European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragnhild","family":"Habberstad","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Trondheim, Norway"},{"name":"Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Trials Unit, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Amadori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maltoni","sequence":"additional","affiliation":[{"name":"Palliative Care Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,10,23]]},"reference":[{"key":"2021122308555006300_B1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: A systematic review of the past 40 years","volume":"18","author":"Van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122308555006300_B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(91)90163-R","article-title":"Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic","volume":"45","author":"Banning","year":"1991","journal-title":"Pain"},{"key":"2021122308555006300_B3","first-page":"131","article-title":"Prevalence, causes and mechanisms of pain in home care patients with advanced cancer","volume":"7","author":"Mercadante","year":"1994","journal-title":"Pain Clinic"},{"key":"2021122308555006300_B4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-3959(95)00076-3","article-title":"Assessment of cancer pain: A prospective evaluation in 2266 cancer patients referred to a pain service","volume":"64","author":"Grond","year":"1996","journal-title":"Pain"},{"key":"2021122308555006300_B5","first-page":"97","volume-title":"Bone and Cancer","author":"Pecherstorfer","year":"2000"},{"key":"2021122308555006300_B6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: The \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2021122308555006300_B7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clon.2011.03.003","article-title":"Mechanisms of cancer-induced bone pain","volume":"23","author":"Middlemiss","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2021122308555006300_B8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2013.08.003","article-title":"Cancer-induced bone pain: Mechanisms and models","volume":"557","author":"Lozano-Ondoua","year":"2013","journal-title":"Neurosci Lett"},{"key":"2021122308555006300_B9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: Definition, prevalence and characteristics","volume":"41","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"2021122308555006300_B10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","article-title":"Prevalence of breakthrough cancer pain: A systematic review and a pooled analysis of published literature","volume":"47","author":"Deandrea","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122308555006300_B11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejpain.2010.08.001","article-title":"Which variables are associated with pain intensity and treatment response in advanced cancer patients?\u2014Implications for a future classification system for cancer pain","volume":"15","author":"Knudsen","year":"2011","journal-title":"Eur J Pain"},{"key":"2021122308555006300_B12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/SPC.0b013e32833d3024","article-title":"Medical management of metastatic bone disease","volume":"4","author":"Vasudev","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"key":"2021122308555006300_B13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJM199610103351507","article-title":"Pharmacologic treatment of cancer pain","volume":"335","author":"Levy","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122308555006300_B14","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"key":"2021122308555006300_B15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0304-3959(02)00102-1","article-title":"Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain","volume":"99","author":"Luger","year":"2002","journal-title":"Pain"},{"key":"2021122308555006300_B16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.pain.2004.04.020","article-title":"Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses","volume":"110","author":"Martucci","year":"2004","journal-title":"Pain"},{"key":"2021122308555006300_B17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00000539-200006000-00028","article-title":"The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients","volume":"90","author":"Sacerdote","year":"2000","journal-title":"Anesth Analg"},{"key":"2021122308555006300_B18","first-page":"106","article-title":"Experimental evidence for immunomodulatory effects of opioids","volume":"521","author":"Sacerdote","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"2021122308555006300_B19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/sj.bjc.6603162","article-title":"Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review","volume":"94","author":"Bell","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122308555006300_B20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.2042-7158.2011.01340.x","article-title":"Pain, analgesia and genetics","volume":"63","author":"Muralidharan","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"2021122308555006300_B21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.forsciint.2010.07.003","article-title":"Pharmacogenetics in palliative care","volume":"203","author":"Kleine-Brueggeney","year":"2010","journal-title":"Forensic Sci Int"},{"key":"2021122308555006300_B22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-pharmtox-061008-103222","article-title":"Progress in genetic studies of pain and analgesia","volume":"49","author":"Lacroix-Fralish","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122308555006300_B23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pharmthera.2009.06.010","article-title":"Genetic modulation of the pharmacological treatment of pain","volume":"124","author":"L\u00f6tsch","year":"2009","journal-title":"Pharmacol Ther"},{"key":"2021122308555006300_B24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-0004.2012.01923.x","article-title":"Opioid genetics: The key to personalized pain control?","volume":"82","author":"Branford","year":"2012","journal-title":"Clin Genet"},{"key":"2021122308555006300_B25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ALN.0b013e3181af6356","article-title":"Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: Selective effect on visceral pain","volume":"111","author":"Arendt-Nielsen","year":"2009","journal-title":"Anesthesiology"},{"key":"2021122308555006300_B26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jpain.2009.04.001","article-title":"Genetic contributions to clinical pain and analgesia: Avoiding pitfalls in genetic research","volume":"10","author":"Kim","year":"2009","journal-title":"J Pain"},{"key":"2021122308555006300_B27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.pain.2011.01.040","article-title":"Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients","volume":"152","author":"Klepstad","year":"2011","journal-title":"Pain"},{"key":"2021122308555006300_B28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bmjspcare-2012-000212","article-title":"Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer: The European Pharmacogenetic Opioid Study (EPOS)","volume":"2","author":"Fladvad","year":"2012","journal-title":"BMJ Support Palliat Care"},{"key":"2021122308555006300_B29","volume-title":"Dosing and conversion chart of opioid analgesics","author":"American College of Physicians","year":"2004"},{"key":"2021122308555006300_B30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jpainsymman.2004.05.008","article-title":"A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients","volume":"29","author":"Fainsinger","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"2021122308555006300_B31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"2021122308555006300_B32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","article-title":"The mini-mental state examination: A comprehensive review","volume":"40","author":"Tombaugh","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"2021122308555006300_B33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S0033291700046730","article-title":"Limits of the \u2018Mini-Mental State\u2019 as a screening test for dementia and delirium among hospital patients","volume":"12","author":"Anthony","year":"1982","journal-title":"Psychol Med"},{"key":"2021122308555006300_B34","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"key":"2021122308555006300_B35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122308555006300_B36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.28.706.49","article-title":"Mendelian proportions in a mixed population","volume":"28","author":"Hardy","year":"1908","journal-title":"Science"},{"key":"2021122308555006300_B37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: Analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"2021122308555006300_B38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2021122308555006300_B39","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122308555006300_B40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/oso\/9780198530220.003.0024","volume-title":"Prognosis in Advanced Cancer","author":"Chow","year":"2008"},{"key":"2021122308555006300_B41","first-page":"912865","article-title":"Survival prediction score: A simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy","volume":"2014","author":"Angelo","year":"2014","journal-title":"ISRN Oncol"},{"key":"2021122308555006300_B42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1748-717X-9-147","article-title":"Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy","volume":"9","author":"Ouyang","year":"2014","journal-title":"Radiat Oncol"},{"key":"2021122308555006300_B43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.canep.2014.05.005","article-title":"Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients","volume":"38","author":"Harries","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2021122308555006300_B44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0885-3924(03)00255-0","article-title":"Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life","volume":"26","author":"Berger","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"2021122308555006300_B45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/pgs.09.13","article-title":"Variation in the COMT gene: Implications for pain perception and pain treatment","volume":"10","author":"Andersen","year":"2009","journal-title":"Pharmacogenomics"},{"key":"2021122308555006300_B46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.pain.2009.07.013","article-title":"Meta-analysis of the relevance of the OPRM1 118A&gt;G genetic variant for pain treatment","volume":"146","author":"Walter","year":"2009","journal-title":"Pain"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/12\/1276\/41860957\/oncolo_19_12_1276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/12\/1276\/41860957\/oncolo_19_12_1276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:32:33Z","timestamp":1717493553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/12\/1276\/6399813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,23]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,10,23]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0174","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,12,1]]},"published":{"date-parts":[[2014,10,23]]}}}